Price
No data yet.
Social Signal Score
Revenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Steven G. Gourlay
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Beta
- 0.89
- Country
- AU
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 14.27
Financials
Revenue
$0.00-100.0%Net Income
$-4.03MEBITDA
$-14.60MFree Cash Flow
$-10.43MEPS (diluted)
$-0.00Shares Outstanding (diluted)
3.30B+14657.5%Operating Expenses
$0.00Cash & Debt
$16.71MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $0.00 | $-15.36M | $-0.00 |
| 2025 | $5.49M | $-14.73M | $-0.00 |
| 2024 | $9.93M | $-13.04M | $-0.01 |
| 2023 | $4.89M | $-10.75M | $-0.01 |
| 2022 | $3.64M | $-9.50M | $-0.01 |
| 2021 | $1.98M | $-3.92M | $-0.00 |
| 2020 | $3.52M | $-5.33M | $-0.00 |
| 2019 | $4.86M | $-9.89M | $-0.01 |
| 2018 | $3.30M | $-6.23M | $-0.01 |
| 2017 | $1.42M | $-3.19M | $-0.00 |
| 2016 | $3.95M | $-3.63M | $-0.01 |
| 2015 | $153.4K | $-5.43M | $-0.01 |
| 2014 | $181.2K | $-440.2K | $-0.00 |
| 2013 | $3.1K | $-164.7K | $-0.00 |
Valuation
ATGGFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80-20.00%Social Signal Score
Mentions (3)
- Newsproactiveinvestors.com·7h ago·Negative
Actinogen Medical enters ‘database lock' to process XanaMIA' data and confirm findings The results for Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF)'s latest Alzheimers disease trial, ‘XanaMIA' are set to be released in mid-November. With final patient visits completed, the company recently entered ‘database lock' to officially process the data and confirm its findings.
View source ↗ - Newsproactiveinvestors.com·2d ago·Neutral
Actinogen Medical closes September quarter with XanaMIA readout in sight Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) closed the September quarter with its pivotal XanaMIA Phase 2b/3 Alzheimer's disease trial on track for topline results in November and a pro-forma cash position of around A$21.9 million. The final patient visit was completed in late September, marking the end of the main treatment and follow-up phase and leaving data finalisation as the key task ahead of the readout.
View source ↗ - Newsproactiveinvestors.com·19d ago·Neutral
Actinogen's Xanamem trial hits key milestone ahead of results - ICYMI Actinogen Medical Ltd (ASX:ACW, OTC:ATGGF) earlier this week completed the final patient visit in its pivotal XanaMIA Phase 2b/3 Alzheimer's disease trial, putting the company on course to report top-line results in November. CFO Will Souter told Proactive that reaching the final patient visit represented “a major milestone in any clinical trial”, following an interim analysis earlier in the year and three meetings of the inde…
View source ↗
Earnings
Wed, Feb 24(in 4 months)
Estimates and results for ATGGF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in ATGGF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.